Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.

Stopped Business decision, not driven by safety concerns; no new safety signals have been observed in the ociperlimab program.

Conditions

• Non-small Cell Lung Cancer (NSCLC)

Interventions

• DRUG: Ociperlimab
• DRUG: Placebo
• DRUG: Tislelizumab
• DRUG: Pembrolizumab
• DRUG: Carboplatin
• DRUG: Cisplatin
• DRUG: Pemetrexed
• DRUG: Paclitaxel
• DRUG: Nab-paclitaxel

Sponsor

Novartis Pharmaceuticals